• linkedin
  • Increase Font
  • Sharebar

    AUA '17 puts emphasis squarely on 'value'

    New era of value-based care permeates policy, clinical presentations



    Steven A. Kaplan, MDDr. Kaplan“This year’s abstracts in BPH are notable for examination of large databases in the use of both medical and surgical therapy for BPH,” said Steven A. Kaplan, MD, professor of urology, Icahn School of Medicine at Mount Sinai, New York. “There will be many presentations on the long-term use of laser and electrosurgical therapy. Updates on minimally invasive surgical alternatives including Rezum, UroLift, and Aquablation will be presented.

    “Finally,” Dr. Kaplan said, “long-term data and adverse events of medical therapies for BPH as well as their predictive role in surgical therapy will be presented.”

    Below are the BPH/LUTS abstracts to watch for at this year's meeting:

    MP02-18: Trends in minimally invasive simple prostatectomy for benign prostatic enlargement in the United States

    Jeffrey Leow


    MP09-10: Tamsulosin prescribing patterns based on a united states health plan claims database

    Bruce Kava


    MP09-17: 5-alpha reductase inhibitors for treatment of benign prostatic hyperplasia does not increase the risk of erectile dysfunction

    Katrina Hagberg


    PD23-11: Aquablation of the prostate for symptomatic benign prostatic hyperplasia: Two-year results

    Peter Gilling


    PD27-02: Comparison of convective radiofrequency water vapor energy ablation of prostate (Rezum) to MTOPS trial cohort

    Nikhil Gupta


    PD27-11: Comparative effectiveness of transurethral resection techniques for benign prostatic hyperplasia – Analysis of an all payer inpatient discharge database

    Christian P. Meyer

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results